Gilead Sciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated April 28, 2026, announces the completion of Gilead Sciences, Inc.'s acquisition of Arcellx, Inc. The transaction was finalized via a tender offer and subsequent merger under Section 251(h) of the Delaware General Corporation Law.
Key Financial Metrics and Transaction Details
- Total Transaction Value: Approximately $7.1 billion in aggregate funds used to consummate the offer and merger, including payments for options and restricted stock units.
- Consideration per Share:
- Cash: $115.00 per share.
- Contingent Value Right (CVR): One CVR per share, representing a potential cash payment of $5.00 per CVR.
- CVR Conditions: The $5.00 payment is contingent on cumulative worldwide sales of Arcellx's anitocabtagene autoleucel (anito-cel) exceeding $6.0 billion on or prior to December 31, 2029. Payment is due on March 31, 2030.
- Tender Offer Results: 38,795,604 shares were validly tendered, representing approximately 77.2% of outstanding shares when combined with shares already owned by Gilead.
Material Changes
The primary material change is the change in corporate structure where Arcellx, Inc. became a wholly-owned subsidiary of Gilead Sciences, Inc. following the merger on April 28, 2026. This follows the initial agreement entered into on February 22, 2026, and the commencement of the tender offer on March 6, 2026.
Outlook, Risks, and Contingencies
- Contingent Liability: Gilead has a potential future cash obligation of up to $5.00 per share for the CVRs, dependent on the commercial performance of the anito-cel product.
- Appraisal Rights: Certain shareholders who properly exercised appraisal rights under Delaware law did not receive the merger consideration and are entitled to a judicial determination of fair value.
- Regulatory Disclosure: The information in this filing is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings.
Key Facts for Investor Verification
- Verify the exact number of shares outstanding to calculate the total potential CVR payout exposure.
- Monitor the commercial launch and sales trajectory of anitocabtagene autoleucel (anito-cel) to assess the likelihood of the $6.0 billion sales threshold being met by 2029.
- Review the impact of the $7.1 billion cash outflow on Gilead's liquidity and debt covenants in subsequent quarterly reports.
- Check for any updates regarding shareholders exercising appraisal rights and the associated legal proceedings.